Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVillemagne, Victor L-
dc.identifier.citationAgeing Research Reviews 2016 Jan 28. pii: S1568-1637(16)30005-8en
dc.description.abstractAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia. The pathological hallmarks of the disease are Aβ amyloid plaques, and tau neurofibrillary tangles, along dendritic and synaptic loss and reactive gliosis. Functional and molecular neuroimaging techniques such as positron emission tomography (PET) using functional and molecular tracers, in conjuction with other Aβ and tau biomarkers in CSF, are proving valuable in the differential diagnosis of AD, as well as in establishing disease prognosis. With the advent of new therapeutic strategies, there has been an increasing application of these techniques for the determination of Aβ burden in vivo in the patient selection, evaluation of target engagement and assessment of the efficacy of therapeutic approaches aimed at reducing Aβ in the brain.en
dc.subjectPositron-Emission Tomographyen
dc.subjectAmyloid beta-Peptidesen
dc.subjectAlzheimer Diseaseen
dc.titleAmyloid imaging: Past, present and future perspectivesen
dc.typeJournal Articleen
dc.identifier.journaltitleAgeing Research Reviewsen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 5, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.